Lidocaine intravesicular - TARIS Biomedical

Drug Profile

Lidocaine intravesicular - TARIS Biomedical

Alternative Names: LiRIS®

Latest Information Update: 31 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TARIS Biomedical
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Interstitial cystitis

Most Recent Events

  • 20 Nov 2017 Allergan completes a phase II trial in Interstitial cystitis in USA and Canada (NCT02395042)
  • 06 May 2016 Efficacy and adverse event data from a phase Ib trial in Interstitial cystitis presented at the Annual Meeting of the American Urological Association (AUA-2016)
  • 02 Sep 2015 Phase-II development for Interstitial cystitis is ongoing in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top